Aspire Biopharma Holdings Inc. has announced positive top-line results from a recent clinical trial of their investigational sublingual aspirin product for the treatment of suspected acute myocardial infarction. The trial demonstrated that Aspire's sublingual aspirin provides a higher and more rapid therapeutic impact compared to standard chewed aspirin tablets. The product was found to be safe and well-tolerated in the study. Aspire plans to review these results with the FDA to potentially pursue accelerated approval. The clinical trial, AB-101, was a randomized crossover bioavailability study involving healthy adults, assessing the safety, tolerability, pharmacokinetics, and pharmacodynamics of the sublingual aspirin.